Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Gallium Ga 68 Gozetotide

Review the clinical trials studying gallium ga 68 gozetotide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-23 of 23

Lu-177-PSMA-617 before Radical Prostatectomy for the Treatment of High Risk Localized Prostate Cancer
Status: Active
Location: 2 locations
Adding Pembrolizumab with or without Olaparib to Radiation and Androgen Deprivation Therapy for the Treatment of Localized High Risk Prostate Cancer
Status: Active
Location: 2 locations
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Status: Active
Location: 2 locations
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Status: Active
Location: 2 locations
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
Status: Active
Location: NYP/Weill Cornell Medical Center, New York, New York
Randomized Phase 2 Trial of Flexible and Extended Dosing of 177Lu-PSMA-617 Molecular Radioligand Therapy (FLEX-MRT)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Re-treatment with 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients with Prostate Cancer, HEATWAVE Trial
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Personalized Ultrahypofractionated Stereotactic Ablative Radiotherapy Guided by [68Ga] PSMA-11 PET/CT Response for the Treatment of High Risk Prostate Cancer, The PULSAR ProPhet Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide with Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
Status: Approved
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
A Radioactive Drug (177Lu–PSMA-617) for the Treatment of PSMA Positive Metastatic and/or Unresectable Liver Cancer
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
18F-Fluciclovine PET/CT for the Detection of Metastatic PSMA-Low Castration Resistant and Neuroendocrine Prostate Cancer
Status: Active
Location: 2 locations
A New Imaging Technique (18F-DCFPyL-PSMA PET/CT) for Detecting Cancer in Patients Planning to Receive 177Lu-Vipivotide Tetraxetan Therapy for Metastatic Castrate-Resistant Prostate Cancer
Status: Active
Location: 2 locations
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Disease Recurrence or Progression in Patients with Glioma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
A Study of 68Gallium PSMA-PET/CT Scans in Patients with Metastatic Bladder Cancer or Melanoma
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Total-body PET/CT (EXPLORER) with Different Radiotracers for the Imaging of Prostate Cancer and Neuroendocrine Tumors
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Evaluation of [Ga-68]PSMA Digital PET/CT for the Detection of Bone Metastases in Patients with Prostate Cancer
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio